BioTelemetry, Inc. (NASDAQ:BEAT) was the target of a significant increase in short interest in the month of December. As of December 29th, there was short interest totalling 3,622,167 shares, an increase of 57.2% from the December 15th total of 2,303,509 shares. Currently, 11.5% of the shares of the stock are sold short. Based on an average trading volume of 542,855 shares, the short-interest ratio is presently 6.7 days.

BEAT has been the subject of several research analyst reports. Off Wall Street initiated coverage on shares of BioTelemetry in a research report on Friday, September 15th. They set a “sell” rating for the company. SunTrust Banks initiated coverage on shares of BioTelemetry in a research report on Monday, October 23rd. They set a “buy” rating and a $41.00 price target for the company. Raymond James Financial initiated coverage on shares of BioTelemetry in a research report on Thursday, October 26th. They set an “outperform” rating and a $37.00 price target for the company. Zacks Investment Research downgraded shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 2nd. Finally, Dougherty & Co restated a “buy” rating and set a $40.00 price target on shares of BioTelemetry in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. BioTelemetry has an average rating of “Hold” and an average price target of $42.86.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Winslow Evans & Crocker Inc. purchased a new stake in BioTelemetry during the 3rd quarter valued at about $109,000. Pinebridge Investments L.P. grew its stake in BioTelemetry by 2.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 3,775 shares of the medical research company’s stock valued at $126,000 after acquiring an additional 75 shares in the last quarter. Victory Capital Management Inc. grew its stake in BioTelemetry by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock valued at $140,000 after acquiring an additional 626 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new stake in BioTelemetry during the 2nd quarter valued at about $207,000. Finally, UBS Asset Management Americas Inc. purchased a new stake in BioTelemetry during the 2nd quarter valued at about $208,000. 82.34% of the stock is owned by institutional investors.

Shares of BioTelemetry (BEAT) opened at $31.60 on Friday. BioTelemetry has a one year low of $21.05 and a one year high of $39.20. The stock has a market cap of $988.45, a PE ratio of 24.12, a P/E/G ratio of 1.40 and a beta of 0.53. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60.

BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings data on Tuesday, November 7th. The medical research company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.09). BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The business had revenue of $81.02 million for the quarter, compared to analysts’ expectations of $82.10 million. During the same period in the prior year, the company posted $0.21 EPS. The firm’s revenue was up 52.7% on a year-over-year basis. equities analysts expect that BioTelemetry will post 0.83 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “BioTelemetry, Inc. (BEAT) Short Interest Update” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/12/biotelemetry-inc-beat-short-interest-update.html.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.